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1. Introduction 
Myasthenia gravis (MG) is a neuromuscular autoimmune disorder caused by binding of 
autoantibodies to molecules involved in neuromuscular transmission: acetylcholine receptor 
(AChR) and muscle specific tyrosine kinase (MuSK). It is characterized by a fluctuant 
weakness.  
The most typical feature is a painless, variable weakness of skeletal muscles that worsens 
with exercise and improves with rest. It may involve different muscles and frequently the 
presenting symptoms are ptosis and/or diplopia due to the involvement of extraocular 
muscles. MG diagnosis is based on a detailed clinical history, on pharmacological test and 
on the measurement of antibodies against the Acetylcholine receptor (AchR-Ab). Some MG 
patients do not have detectable AChR-Ab and have been defined as “seronegative” (SNMG) 
(Vincent 2004). A high proportion of these patients have purely ocular symptoms (ocular 
MG). Seronegative generalized myasthenia is proving to be heterogeneous on clinical, 
immunological and histopathological features. A variable proportion of SNMG patients has 
antibodies against MuSK. These antibodies are directed against the extracellular domain of 
MuSK and inhibit the agrin-induced AChR clustering in muscle myotubes. Although the 
role of these antibodies in causing myasthenic symptoms in vivo is not still clear, MuSK 
antibodies appear to define a group of patients. 
2. Pathophysiology  
The neuromuscular junction (NMJ) is the communication between nerve and muscle where 
the electrical nerve impulse is translated into an electrical stimulation to initiate muscle 
contraction [1]. Acetylcholine (ACh) acts as the chemical messenger between the nerve fibre 
and the postsynaptic muscle membrane. ACh is released into the synaptic cleft on nerve 
depolarization and rapidly diffuses to bind to ACh receptors (AChRs). AChRs can be either 
nicotinic or muscarinic. The nicotinic AChR is a multimeric protein comprised in adults of 
two α subunits and one each of β, δ, and ε subunits. The nicotinic AChR is a multimeric 
protein made of two α subunits, which in turn are made of β, δ, and ε subunits. Each α 
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subunit has a binding site for ACh. Muscle-specific tyrosine kinase (MuSK) is an AChR-
associated protein involved in clustering of AChR during synapse formation and is 
expressed in the mature NMJ [2]. 
Autoimmune disorders result from the loss of tolerance to self-antigens. In the case of 
myasthenia gravis (MG), an autoimmune disorder characterized by clinical fatigable 
weakness, the body raises an autoimmune attack on its own muscle endplate, initiated by 
antibody binding to AChR or, less frequently, to MuSK, resulting in abnormal 
neuromuscular transmission and muscle weakness.  
Approximately 80% of patients have detectable serum antibodies against AChR  that reduce 
AChR number and impair their function at the neuromuscular endplate. About 15-30% of 
MG patients do not have detectable AChRAb and are defined as seronegative. These patients 
may have purely ocular symptoms but a small proportion has generalized weakness. About 
half of seronegative MG cases has antibodies against a muscle-specific tyrosine-kinase 
protein (MuSK-Ab). The role of MuSK-Ab in the pathogenesis of MG is still unclear. These 
antibodies probably impair neuromuscular transmission, as MuSK protein plays a critical 
role in postsynaptic differentiation and in AChR gene expression [3]. MuSK is a 
transmembrane polypeptide selectively expressed in skeletal muscle. It is part of the agrin-
receptor, an essential protein in building the neuromuscular synapses. Experimental data 
show that agrin-induced activation of MuSK by tyrosine phosphorylation results in 
aggregation and expression of specific muscle proteins, AChR included, and in AChR 
phosphorylation [4]. Anti-MuSK serum antibodies may bind the external domain and 
reduce the agrin-induced expression of AChR in myotubes in vitro [5]. Selcen et al. 
Demonstrated in a single patient on intercostal muscle biopsy, that MuSK-Ab do not cause a 
reduction of MuSK or AChR in neuromuscular plate [6], but its presence in the 
neuromuscular junction causes a 20% decrease of AChR-clusters and a decrease of agrin-
induced AChR-clusters according to study in all patients [7]. MuSK-Ab also do not cause 
internalization of AChR, as demonstrated in AChR-Ab MG [7].  
The thymus is a critical organ for T-cell education and elimination of auto-reactive T-cells, 
and plays a major role in MG. Thymic abnormalities are frequently present in MG, including 
hyperplasia in about 65% of cases and thymoma in 10%. The expression of AChR by myoid 
cells in the thymus plus the inflammatory environment within the MG thymus, contribute 
to the induction and maintenance of the anti-AChR autoimmune response [8]. 
3. Epidemiology 
MG used to be considered a rare disease, however incidence and prevalence rates have 
increased over time, partly as a result of increased of diagnosis, and results of prolonged 
survival with the disease for new improvement protocol of patients [9]. the current 
incidence rates range from 9−21 per million population, with prevalence rates of 50–125 
cases per million population worldwide. 
The onset and incidence of MG is influenced by age and gender and MG was first thought to 
be a condition of the young female and old male. Epidemiological data show that women 
are most frequently affected than men; age at onset in MG patients with MuSK-Ab occurs 
predominantly before 40 years, at a younger age than MG cases with AChR-Ab [9].  Women 
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are frequently more affected than men [10; 11]. Recent reports indicate that MG may be 
under-diagnosed in the elderly [12]. 
4. Clinical features  
Patients with MG present weakness in specific muscle groups. The main feature is a 
fluctuant variable weakness of skeletal muscles that worsens with exercise and improves 
with rest. The onset in about the 65% of patients is characterised by ocular symptoms, such 
as ptosis and diplopia, the remaining 25% of patients shows bulbar weakness, resulting in 
slurred or nasal speech, voice alterations or difficulty in chewing or swallowing. Limb 
weakness is a less common initial complaint [13; 14]. The degree of weakness may vary 
during the day, but, generally it worsens with exercises and improve with rest.  
The progression of muscle weakness in MG usually occurs in a craniocaudal direction,  
beginning with ocular, facial, lower bulbar muscles, and progressing to torso and limb 
muscle involvement. Maximal weakness occurs within the first year following the onset of 
the disease in approximately two-thirds of  the cases [15; 16]. Up to 50% of patients who 
presents ocular MG will progress to generalized MG within 6 months, rising up to 80% 
within 2 years [14].  
However, in around 10−40% of cases, muscle weakness remains restricted to the ocular 
muscles. [13] 
MG with anti-MuSK-Ab has a different phenotype from the remaining seronegative MG; in 
most of the cases symptoms at onset includes nasal voice, weakness of facial and limb 
muscles and respiratory muscles [17; 16]. Patients can show a severe predominantly facio-
bulbar weakness with dyspnea and nasal speech; dysphagia sometimes is so severe that it 
leads to an important weight loss. In some cases, only ocular muscles can be affected [18]. A 
significant association between bulbar/facial muscles weakness and muscular atrophy has 
been described in MuSK-positive patients [7],  this could justify the selective and typical 
bulbar involvement. 
MG remains a challenging disease to diagnose due to its fluctuating character and to the 
similarity of symptoms to those of other disorders; the mean time to diagnosis is often over 
1 year [13; 14]. Seronegative MG with anti-MuSK antibodies still remains a diagnostic 
challenge, because of its fluctuating character and  the similarity of symptoms to with other 
disorders. Mean time to diagnosis is often over 1 year [13; 14].  The diagnostic value of 
neostigmine or edrophonium test and repetitive stimulation is low [15], while single fibre 
EMG has very high sensitivity. 
MG with MuSK-Ab is responsive to standard therapy, but needs higher drug dosages than 
MG AChR-Ab positive [19], MuSK-positive patients frequently develop hypersensitivity to 
anticholinesterase drugs [15]. Instead, seronegative MG without MuSK-Ab seems to have a 
similar or less severe clinical course than seropositive ones and a similar response to 
pharmacological treatment [20]. 
5. Treatment  
The treatment of MG includes both a surgical and a therapeutic approach.  
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Thymectomy is currently performed in patients with thymoma (usually by median 
sternotomy) and in generalized AChR-positive MG (cervicotomy, VATS, VATET), where it 
appears to increase the rate of remission. In MuSK-positive MG, thymectomy is generally 
thought to be of less value and the question of whether it has a role in the disease treatment 
is controversial. This opinion is based on clinical reports and morphological studies. These 
studies [17, 19], even if performed in small patient series and presenting potential 
confounding factors such as the effect of immunosuppressive treatment and the inclusion of 
patients with different disease severity and duration, have altogether failed to show a better 
outcome in thymectomised than in unthymectomised MuSK-positive patients, both in terms 
of remission rate and need for immunosuppressive therapy. 
Drugs: Symptomatic drugs, such as anticholinesterase, are generally well tolerated and 
represent the first-line treatment in most patients, they can improve muscle strength in a 
minority of cases [21]. Immunosuppressive therapy is indicated for patients with symptoms 
not controlled with acetyl-cholinesterase inhibitors. Different drugs have been used alone or 
in combination:  corticosteroids, azathioprine, cyclosporine, cyclophosphamide, 
mycophenolate mofetil, tacrolimus, and rituximab [21] (Table I). In the AChR-positive 
disease, immunosuppressive therapy is highly effective. Short-term treatments, such as 
plasma-exchange (PE) and intravenous immunoglobulin (IVIG), are used to treat patients 
with severe, rapidly progressing disease. The response to therapy in MuSK-positive MG 
patients seems to be different from that in AChR-Ab positive. In MuSK-positive MG the 
response to anchtiolinesterase is generally unsatisfactory. A general impression is that 
MuSK MG patients fare worse than AChR-Ab-positive patients [22]. This impression is 
based on the remission rate. When comparing therapeutic results in MuSK-MG and AChR-
MG in a meta-analysis, Evoli et al.[17] found a significant difference in remission rates: 10%–
35% in MuSK-MG versus 24%–58% in AChR-MG. Because of the disease severity and the 
poor response to acetyl-cholinesterase inhibitors, the majority of MuSK-positive patients 
require immunosuppressive therapy [22].    
6. Histopathological changes in muscles and thymus 
Thymus pathology in MuSK-positive patients is not so far available because of the relatively 
minor incidence of this subgroup in the population of myasthenic patients. MG is initiated 
within the thymus by immunogenic presentation of locally produced nicotinic acetylcholine 
receptor (AChR) to potentially autoimmune T cells [23]. Because the thymus is the central 
organ for immunological self-tolerance, it is reasonable to suspect that thymic abnormalities 
cause the breakdown in tolerance that causes an immune-mediated attack on AChR in 
myasthenia gravis. The thymus contains myoid cells that express the AChR antigen, antigen 
presenting cells, and immunocompetent T-cells. Thymus tissue from patients with 
myasthenia gravis produces AChR antibodies when implanted into immunodeficient mice. 
However, in AChR-negative/MuSK-positive MG, the thymus does not appear to play such 
an important role in the pathogenesis as it is thought to play in non- thymoma seropositive 
MG [24]. 
Pathological studies often demonstrate thymic hyperplasia in AChR-Ab positive and in 
AChR-ab negative/MuSK-negative patients. In contrast, in the thymuses from MuSK-
positive patients, lymphoid follicles with germinal centres are not found and the 
perivascular space harbors amounts of lymphoid cells are significantly less than in the  
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AChR-Ab patients. Thymus changes in these cases resemble those in normal aging [25]. 
Thymectomy often results in clinical improvement in AChR-Ab positive patients, 
suggesting a role for the thymus in the initiation or propagation of the autoimmune attack 
on the myocyte. The role of thymectomy in MuSK-positive MG remains uncertain. Recent 
studies reported no reduction in immunosuppressive therapy or reduction in MuSK 
antibody titles following thymectomy, and no difference in clinical status between MuSK 
MG patients with or without thymectomy [17]. 
Diagnosis procedure in Myastenia gravis and muscle biopsy morphology 
The diagnosis of MG is based on clinical, laboratory and instrumental procedures; muscles 
biopsy is performed only to exclude alternative diagnosis therefore the number of muscle 
biopsies available is limited. Muscle biopsy of intercostal muscles in mostly used in 
congenital myasthenia. The biopsied muscles are usually the limb muscles (quadriceps, 
deltoid) thus the pathology could be different in bulbar muscles that can’t be examined.  
The muscle biopsies of AChR-Ab positive patients shows focal and usually non-specific 
changes. They include atrophy of type 2 fibers, and sometimes atrophy of type 1 fibers, and 
rarely the presence of small angulated fibers and fiber type grouping, suggestive of 
denervation [26]. Ultrastrucural images of ednplate show the presence of reduced folds of 
the junction, and debris from them accumulates between the nerve and the muscle 
membrane. Complement and immune complexes can be demonstrated on the post-synaptic 
membrane, as well as  the binding of autoantibodies in the serum from affected patients to 
neuromuscular junction has been observed. In the past no study was done to study electron 
microscopy or histopathology of MuSK positive biopsies. In our study [27], we analysed 
muscle biopsy of 13 myasthenic patients (8 women and 5 men), whose diagnosis was based 
on standard criteria. Seven patients were positive for AChR-Ab (serum AChRAb > 0.25 
nmol/l) and six positive for MuSK-Ab and negative for AChR-Ab. Our findings reveal that 
MG associated with antibodies against MuSK and MG associated to AChR-Ab show 
different histopathological features. Atrophy factor in skeletal muscle biopsies is higher for 
both type I and type II fibers in AChR-Ab positive cases: this feature agrees with the 
observation that the disease affects more severely the limb than the bulbar muscles (Figure 
1). Atrophy of type II fibers might be explained by a reduced muscle strength and disuse 
atrophy in both groups of patients. Skeletal muscle fibres of MuSK-positive cases are 
relatively preserved by atrophy, and this could be due either to a focal action of MuSK 
antibodies or to the fact that bulbar muscles are the onlyone partially susceptible to MuSK 
antibodies. In this study we observed prominent signs of mitochondrial involvement, such 
as COX-negative fibers or mitochondrial aggregates and myofibrillar disarray, in MuSK-
positive patients, indicating that mitochondrial function could have a role in this disease 
(Figure 2). The presence of several COX negative fibers in patients under 40 years can be 
regarded as abnormal, aince SOX.fibres are not usually seen until after 50 years. In contrast, 
AChR-Ab positive showed only mild and unspecific myopathic changes, but often muscle 
fibre atrophy and few aggregates of normally shaped mitochondria were observed.  
The ultrastructured study of biopsy from MuSK-positive patients [27] confirmed the pattern 
of severe myopathic changes, such as swollen mithochondria, myofibrillar loss, and 
sarcoplasmic reticulum lipid vesicles associated with enlarged mithocondria with 
electronlucent matrix and fragmented cristae [28]. Mitochondria are aggregated both in the 
subsarcolemmal and intermyofibrillar areas (Figure 3), adjacent to normal mitochondria. 
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Fig. 1. Light microscopy. Acid ATP-ase stain 
shows type I fibre grouping in one AChR-Ab 
patient 
Fig. 2. COX stain shows 2 COX-negative 
fibers  (star) in one AChR-Ab patient. 
Ultrastructural studies show also that MuSK-positive cause a 20% decrease of AChR 
number on the surface of the postsynaptic membrane, clusters of AChR in MuSK-positive 
patients appear larger than in AChR-Ab positive cases, and this could be due to cluster 
dispersion induced by MuSK antibodies (Figure 4). These antibodies cause a decrease of 
AChR agrin-induced expression [2, 4]. The presence of fiber type grouping in many AChR+ 
patients might be explained by blockage of AChR receptor binding that causes the 
internalization and degradation of AChR and consequently a denervation of affected muscle 
[29]. Fiber type grouping in cases with anti-MuSK-Ab is less frequently observed. In a recent 
study of Rostedt Punga et al. [30] deltoid muscle of 10 MuSK+ and 40 AChR+ patients were 
compared. They analized mtDNA in the cases that presented histological mitochondrial   
 
 
Fig. 3. NADH-TR stain. 
Subsarcolemmal 
mitochondrial rims in one 
MuSK-positive patient 
Fig. 4.  Swelling of mitochondria and cristae disruption  in 
MuSK-positive. Dense mitochondria were disposed 
perpendicular to the sarcomeres 
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abnormalities at muscle specimens, and they found frequent deletions in mtDNA, 
supporting the morphological date. 
In conclusion, atrophy could bedue to a functional denervation in AChR-Ab positive 
patients while, in MuSK-positive patients, there are mild myopathic changes with 
prominent mitochondrial abnormalities.  
Clinical aspects, electrophysiological tests, immunological presentation, thymus pathology 
and the therapeutic response implicate that MG MuSK-positive is a specific subgroup of 
seronegative MG, and has to be analised as a peculiar muscle pathology. Treatment and 
diagnosis, as well as prognosis and surgical approach is different in MG with MuSK-Ab. 
The clinician should be alerted of this different bfeatures and have a different approach to 
this tipe of myasthenia gravis.   
7. Anti-MuSK patients in clinical practice 
In our Neuromuscular Centre Database we collected 279 MG patients: 171 female and 108 
male. AChR-Ab were positive in 143 patients positive (51%). Among the 97 seronegative 
patients (35%) only 46 (16%) presented a generalized MG: MuSK-Ab were positive in 9 of 
them (19%). 
Diagnosis was based on standard criteria [13,31], including symptoms of fluctuating muscle 
fatigue, supported by an electromyographic pattern (repetitive nerve stimulation). Patients 
were periodically examined at the Neuromuscular Diseases Centre, University of Padova. 
MG classification had been performed according to the Myasthenia Gravis Foundation of 
America. MGFA class I includes only ocular onset; class II includes mild generalized onset; 
class III includes moderate generalized onset; class IV includes severe generalized fatigue; 
class V patients need intubation. For classes II–IV, a further classification in subclass ‘a’ 
indicates prevalent limb muscle involvement, while subclass ‘b’ includes patients with 
predominant bulbar muscle involvement. Muscle strength was determined using MRC 
score (Medical Research Council) of every biopsied muscle at time of diagnosis. MRC score: 
5 – normal force, 4 – movement against gravity and resistance, 3 – movement just against 
gravity, 2 – movement is possible just in absence of gravity, 1 – muscle contraction is visible 
but no movement is seen and 0 – no contraction is visible. Plus and minus indicates an 
intermediate degree of muscle strength. The clinical data collected included: age at onset, 
sex, therapy assessment and muscle strength conditions at the time of diagnosis. 
The MuSK-positive patient were 8 females and one male with a mean age at onset of 47 ± 
19.7 (Table I). At onset 2 of them presented generalized symptoms and were both in II-a 
MGFA score class; 7 (78%) presented bulbar symptoms: 2 were in class II-b, 3 in class III-b 
and 2 in class IV-b of MGFA score. Four (44%) were thymectomised: one had a thymic 
atrophy and 3 (75%) thymic hyperplasia. 
Biopsy was done in seven patients at the time of MG diagnosis. Histopathological 
investigations were performed blind to the patient’s clinical status. Muscle biopsies of 
patients were collected after informed consent; all procedures were conducted after 
obtaining the approval from the University Review Board. 
At the last follow-up visit, after a mean duration of disease of 10 years, six patients were 
improved: two patients were asymptomatic, four were in class II-b. Two patients were 
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unchanged and only one got worse. Corticosteroids associated with anticholinesterases 
were sufficient only in one patient; 8 (89%) needed an additional treatment with 
immunosuppressive drug: four used azathioprine and had to change therapy for 
unsatisfactory response to the first-one: three pass to cyclosporine and one to 
mycophenolate mofetil. One patient used cyclosporine since MG onset. Eight patients (89%) 
were treated with IVIG and had a clinical improvement. PE was used in three patients, with 
a minor  response. 
 
Agent 
(trade names) 
Initial dose Maintenance dose Onset of action 
Prednisone 15–20mg q.d., 
Increasing by 5–10mg 
q2–3 days  
1.5 mg/kg/day, 
followed by slow 
alternate day taper 
(taper by 5–10mg a 
month) 
2–4 weeks 
Azathioprine 50mg q.d. * Increase by 50mg 
increments q 2–4 weeks 
to target of 2–3 mg/kg 
2–10 months for 
initial response, up 
to 24 months for 
peak 
Cyclosporin 100mg b.i.d. ^  Increase slowly as 
needed to 3–6 mg/kg 
on 
b.i.d. schedule 
1–3 months 
Mycophenolate 500mg b.i.d. 1000–1500mg b.i.d. 2–12 months 
Cyclophosphamide 3–5 mg/kg/day,  
can be preceded by 
intravenous pulse 
2–3 mg/kg a day 2–6 months 
Tacrolimus/FK-506 3–5 mg/day or  0.1 
mg/kg/day 
Increase up to 5–7mg a 
day following dosage 
of plasmatic levels 
1–3 months 
Rituximab 375 mg/m2 IV every 
1–2 weeks for 4 weeks 
None or 375 mg/m2 
every 4–10 weeks for a 
few months 
1–3 months 
Etanercept 25mg s.c. ° twice 
weekly 
25mg s.c. twice weekly 2– months 
^ b.i.d., twice daily;  
* q.d., daily; 
° s.c., subcutaneous 
Table II. Commonly used immunosuppressant agents for myasthenia gravis 
8. Case Report 
A 36 years-old woman presented 2 years history of progressive dyspnea and fatigue. She 
complained of diffuse weakness. She had no complaint for  pain or cramps but noticed an 
increased difficulty in climbing stairs. She had a nasal speech, but denied diplopia and 
ptosis. She had lost 40 kg for a progressive and severe difficulty in swallowing solid food. 
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Past medical history was positive only for a hiatus hernia and esophageal gastrointestinal 
reflux. EMG, brain MRI and mediastinial CT gave normal results. Pneumological evaluation 
showed a high breathways obstructive pattern.  
Examination revealed normal vital signs: her gait was slow; strength testing revealed mild 
weakness in triceps (4+/5), deltoid and brachioradialis (4/5), gastrocnemius (5-/5) and in 
orbicularis oculi et oris. Extensive auto-immunity battery examination gave normal results, 
except for the research of anti-MuSK antibodies, that were positive. Pneumological 
evaluation showed a slight restrictive pattern.  
Logopedic evaluation documented dysphonia and slowed deglutition. There was a depressive 
psychological profile. Electrodiagnostic studies with repetitive nerve stimulation were normal. 
Muscle biopsy revealed atrophy of muscle fibers, minicores and mitocondrial alterations. 
Treatment with trazodone and tocopherol was started. Despite this treatment, her condition 
worsened because of  persistent dysphagia and rhinolalia; respiratory insufficiency became so 
severe that she needed a mechanical assisted ventilation during the night.  IVIg and 
cyclosporine reversed her condition and brought a permanent improvement.  
The final diagnosis was: MuSK-positive myasthenia with anorexia and ventilatory 
insufficiency. 
This study is supported by Eurobiobank, TREAT-NMD, Telethon GUP 07001 and Grant 
from Italian Ministry of Education. We thank also myasthenia gravis patients that 
collaborated to this study. 
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Myasthenia gravis is presently an incurable antibody-mediated autoimmune disorder characterized by
generalized voluntary skeletal muscle weakness. The cause of the weakness is a defect at the neuromuscular
junction level, in which autoimmune antibodies block the receptors responsible for initiating muscular
contraction. Literally translated from its Latin and Greek etymological roots, myasthenia gravis means "grave
muscle weakness". Fortunately, advances in modern medicine have resulted in a reduction of the truly "grave"
outcomes for those inflicted but, without a cure, the gravity surrounding the disease remains
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